Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have expanded their use in cardiovascular medicine. In individuals with type 2 diabetes, long-acting GLP-1RAs have shown a reduction in major adverse cardiovascular events (MACE). Extended benefits have been observed in adults with established cardiovascular disease and overweight or obesity without diabetes, as demonstrated by oral semaglutide. Cardiovascular noninferiority of tirzepatide to dulaglutide was established in a clinical trial. Obesity-related heart failure with preserved ejection fraction (HFpEF) has shown responsiveness to treatment with semaglutide, improving symptoms and physical function, while tirzepatide reduces worsening heart failure events.
Randomized human studies have indicated effects on adiposity, haemodynamic burden, inflammation, and cardiorenal outcomes. Endothelial, coronary microvascular, and direct myocardial mechanisms require further clinical validation. The evidence integrates randomised outcomes with observational and mechanistic signals, offering a phenotype-directed treatment algorithm.
This algorithm considers atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium-glucose cotransporter 2 inhibitor use, and patient-specific constraints. Treatment decisions should be guided by indication-specific outcome evidence, rather than weight-loss magnitude or cross-trial comparisons.